-+ 0.00%
-+ 0.00%
-+ 0.00%
Regarding whether the price reduction of Yao Ming Junuo's CAR-T drug into the basic medical insurance catalogue was a “loss and profit”, the relevant management of Pharmaceutical Ming Junuo recently denied this statement and stated that it was a prudent decision that “opened up room for volume on a profitable basis”. After entering medical insurance, they are very confident that the company will gradually achieve profits. In terms of production capacity arrangements, the company estimates that the current production capacity will basically meet market demand in 2027, and the company is also preparing for further expansion of production. Pharmaceutical Juno-B announced yesterday evening that the medical insurance payment standard for the company's CAR-T product Benoda® is 288,600 yuan, effective from January 1, 2027. Management expects that domestic substitution and scale effects will continue to reduce the unit production cost of this product by more than 65%.
Share
Listen to the news
Regarding whether the price reduction of Yao Ming Junuo's CAR-T drug into the basic medical insurance catalogue was a “loss and profit”, the relevant management of Pharmaceutical Ming Junuo recently denied this statement and stated that it was a prudent decision that “opened up room for volume on a profitable basis”. After entering medical insurance, they are very confident that the company will gradually achieve profits. In terms of production capacity arrangements, the company estimates that the current production capacity will basically meet market demand in 2027, and the company is also preparing for further expansion of production. Pharmaceutical Juno-B announced yesterday evening that the medical insurance payment standard for the company's CAR-T product Benoda® is 288,600 yuan, which will take effect from January 1, 2027. Management expects that domestic substitution and scale effects will continue to reduce the unit production cost of this product by more than 65%.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending